Inhibition of p38α MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1963-1975

  Navas, Tony ^a   Zhou, Li ^b   Estes, Myka ^c   Haghnazari, Edwin ^a   Nguyen, Aaron ^a   Mo, Yongkai ^b   Pahanish, Perry ^b   Mohindru, Mani ^b   Cao, Tim ^a   Higgins, Linda ^a   Platanias, Leonidas C ^d   List, Alan ^c   Verma, Amit ^b  

^a SCIOS INC   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cytokine production and paraneoplastic conditions neoplasia; Myeloid leukemias and dysplasias neoplasia; Signal transduction neoplasia

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SCIO 468; SCIO 469; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR; SCIO-469;

APOPTOSIS; BONE MARROW; BONE MARROW CELL; CELL PROTECTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MICROARRAY; DRUG ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; STROMA CELL; AGED; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; PARACRINE SIGNALING; PATHOLOGY; SECRETION;

AGED; BONE MARROW; CYTOKINES; HUMANS; INDOLES; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MYELODYSPLASTIC SYNDROMES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARACRINE COMMUNICATION; PROTEIN KINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55049116044     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802322919     Document Type: Conference Paper

References (62)

1. Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P. Sanz, G. et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, pp. 2079-2088.
2. Heaney, M. L. and Golde, D. W. (1999) Myelodysplasia. N Engl J Med, 340, pp. 1649-1660.
3. Verma, A. and List, A. F. (2005) Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep, 4, pp. 429-435.
4. Allampallam, K., Shetty, V., Mundle, S., Dutt, D., Kravitz, H. Reddy, P. L. et al. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol, 75, pp. 289-297.
5. Claessens, Y. E., Park, S., Dubart-Kupperschmitt, A., Mariot, V., Garrido, C. Chretien, S. et al. (2005) Rescue of early stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant negative form of FADD. Blood, 105, pp. 4035-4042.
6. Zorat, F., Shetty, V., Dutt, D., Lisak, L., Nascimben, F. Allampallam, K. et al. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol, 115, pp. 881-894.
7. Deeg, H. J., Beckham, C., Loken, M. R., Bryant, E., Lesnikova, M. Shulman, H. M. et al. (2000) Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma, 37, pp. 405-414.
8. Allampallam, K., Shetty, V., Hussaini, S., Mazzoran, L., Zorat, F. Huang, R. et al. (1999) Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res, 19, pp. 5323-5328.
9. Mundle, S. D., Reza, S., Ali, A., Mativi, Y., Shetty, V. Venugopal, P. et al. (1999) Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett, 140, pp. 201-207.
10. Dufour, C., Corcione, A., Svahn, J., Haupt, R., Battilana, N. and Pistoia, V. (2001) Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol, 115, pp. 1023-1031.
11. Welsh, J. P., Rutherford, T. R., Flynn, J., Foukaneli, T., Gordon-Smith, E. C. and Gibson, F. M. (2004) In vitro effects of interferon-gamma and tumor necrosis factor-alpha on CD34+ bone marrow progenitor cells from aplastic anemia patients and normal donors. Hematol J, 5, pp. 39-46.
12. Koike, M., Ishiyama, T., Tomoyasu, S. and Tsuruoka, N. (1995) Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res, 19, pp. 639-644.
13. Dufour, C., Corcione, A., Svahn, J., Haupt, R., Poggi, V. Beka'ssy, A. N. et al. (2003) TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood, 102, pp. 2053-2059.
14. Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, T., Kamiyama, R. and Hirokawa, K. (1997) Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia, 11, pp. 2049-2054.
15. Bellamy, W. T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B. Frutiger, Y. et al. (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood, 97, pp. 1427-1434.
16. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V. Nadaf, S. et al. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92, pp. 4150-4166.
17. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E. Thomas, D. et al. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96, pp. 2240-2245.
18. Kurzrock, R., Kantarjian, H., Wetzler, M., Estrov, Z., Estey, E. Troutman-Worden, K. et al. (1993) Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol, 21, pp. 80-85.
19. Griffin, J. D., Rambaldi, A., Vellenga, E., Young, D. C., Ostapovicz, D. and Cannistra, S. A. (1987) Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood, 70, pp. 1218-1221.
20. Dinarello, C. A. (1996) Biologic basis for interleukin-1 in disease. Blood, 87, pp. 2095-2147.
21. Bagby, Jr. GC (1989) Interleukin-1 and hematopoiesis. Blood Rev, 3, pp. 152-161.
22. Grigorieva, I., Thomas, X. and Epstein, J. (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol, 26, pp. 597-603.
23. Yasui, H., Hideshima, T., Richardson, P. G. and Anderson, K. C. (2006) Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol, 132, pp. 385-397.
24. Tefferi, A. (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med, 342, pp. 1255-1265.
25. Flores-Figueroa, E., Arana-Trejo, R. M., Gutierrez-Espindola, G., Perez-Cabrera, A. and Mayani, H. (2005) Mesenchymal stem cells in myelodysplastic syndromes: Phenotypic and cytogenetic characterization. Leuk Res, 29, pp. 215-224.
26. Narendran, A., Hawkins, L. M., Ganjavi, H., Vanek, W., Gee, M. F. Barlow, J. W. et al. (2004) Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol, 21, pp. 209-221.
27. Tauro, S., Hepburn, M. D., Bowen, D. T. and Pippard, M. J. (2001) Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica, 86, pp. 1038-1045.
28. Aizawa, S., Nakano, M., Iwase, O., Yaguchi, M., Hiramoto, M. Hoshi, H. et al. (1999) Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res, 23, pp. 239-246.
29. Deeg, H. J. (2002) Marrow stroma in MDS: Culprit or bystander?. Leuk Res, 26, pp. 687-688.
30. Aizawa, S., Hiramoto, M., Hoshi, H., Toyama, K., Shima, D. and Handa, H. (2000) Establishment of stromal cell line from an MDS RA patient which induced an apoptotic change in hematopoietic and leukemic cells in vitro. Exp Hematol, 28, pp. 148-155.
31. Young, N. S. and Maciejewski, J. (1997) The pathophysiology of acquired aplastic anemia. N Engl J Med, 336, pp. 1365-1372.
32. Kook, H., Zeng, W., Guibin, C., Kirby, M., Young, N. S. and Maciejewski, J. P. (2001) Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol, 29, pp. 1270-1277.
33. Selleri, C., Maciejewski, J. P., Catalano, L., Ricci, P., Andretta, C. Luciano, L. et al. (2002) Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: In vitro and in vivo studies. Cancer, 95, pp. 1911-1922.
34. Sloand, E. M., Mainwaring, L., Fuhrer, M., Ramkissoon, S., Risitano, A. M. Keyvanafar, K. et al. (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood, 106, pp. 841-851.
35. Sloand, E. M., Pfannes, L., Chen, G., Shah, S., Solomou, E. E. Barrett, J. et al. (2007) CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood, 109, pp. 2399-2405.
36. Johnson, G. L. and Lapadat, R. (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298, pp. 1911-1912.
37. Kumar, S., Boehm, J. and Lee, J. C. (2003) p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov, 2, pp. 717-726.
38. Platanias, L. C. (2003) Map kinase signaling pathways and hematologic malignancies. Blood, 101, pp. 4667-4679.
39. Navas, T. A., Mohindru, M., Estes, M., Ma, J. Y., Sokol, L. Pahanish, P. et al. (2006) Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood, 108, pp. 4170-4177.
40. Navas, T. A., Nguyen, A. N., Hideshima, T., Reddy, M., Ma, J. Y. Haghnazari, E. et al. (2006) Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia, 20, pp. 1017-1027.
41. Verma, A., Deb, D. K., Sassano, A., Kambhampati, S., Wickrema, A. Uddin, S. et al. (2002) Cutting edge: Activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol, 168, pp. 5984-5988.
42. Mohindru, M., Kang, B. and Kim, B. S. (2006) Initial capsid-specific CD4(+) T cell responses protect against Theiler's murine encephalomyelitisvirus-induced demyelinating disease. Eur J Immunol, 36, pp. 2106-2115.
43. Kapoun, A. M., Liang, F., O'Young, G., Damm, D. L., Quon, D. White, R. T. et al. (2004) B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res, 94, pp. 453-461.
44. Nguyen, A. N., Stebbins, E. G., Henson, M., O'Young, G., Choi, S. J. Quon, D. et al. (2006) Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res, 312, pp. 1909-1923.
45. Haneline, L. S., Broxmeyer, H. E., Cooper, S., Hangoc, G., Carreau, M. Buchwald, M. et al. (1998) Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood, 91, pp. 4092-4098.
46. Devine, S. M., Flomenberg, N., Vesole, D. H., Liesveld, J., Weisdorf, D. Badel, K. et al. (2004) Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol, 22, pp. 1095-1102.
47. List, A. F. (2001) Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist, 6, pp. 24-31.
48. Nath, P., Leung, S. Y., Williams, A., Noble, A., Chakravarty, S. D. Luedtke, G. R. et al. (2006) Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. Eur J Pharmacol, 544, pp. 160-167.
49. Verma, A., Deb, D. K., Sassano, A., Uddin, S., Varga, J. Wickrema, A. et al. (2002) Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem, 277, pp. 7726-7735.
50. Means, Jr. RT, Dessypris, E. N. and Krantz, S. B. (1992) Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol, 150, pp. 59-64.
51. Jelkmann, W., Wolff, M. and Fandrey, J. (1990) Modulation of the production of erythropoietin by cytokines: In vitro studies and their clinical implications. Contrib Nephrol, 87, pp. 68-77.
52. Werner, S. L., Barken, D. and Hoffmann, A. (2005) Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science, 309, pp. 1857-1861.
53. Brinkman, B. M., Telliez, J. B., Schievella, A. R., Lin, L. L. and Goldfeld, A. E. (1999) Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2- and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression. J Biol Chem, 274, pp. 30882-30886.
54. Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C. Volk, H. D. et al. (1999) MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol, 1, pp. 94-97.
55. Legare, R. D. and Gilliland, D. G. (1995) Myelodysplastic syndrome. Curr Opin Hematol, 2, pp. 283-292.
56. Greenberg, P. L. (1998) Apoptosis and its role in the myelodysplastic syndromes: Implications for disease natural history and treatment. Leuk Res, 22, pp. 1123-1136.
57. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A. Feldman, E. et al. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med, 355, pp. 1456-1465.
58. List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D. Fuchs, D. et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 352, pp. 549-557.
59. Tai, Y. T., Li, X. F., Catley, L., Coffey, R., Breitkreutz, I. Bae, J. et al. (2005) Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. Cancer Res, 65, pp. 11712-11720.
60. Anderson, K. C. (2005) Lenalidomide and thalidomide: Mechanisms of action - similarities and differences. Semin Hematol, 42, pp. S3-S8.
61. Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M., Parmar, S. Greenberg, P. et al. (2006) Phase I/II, Randomized, MultiCenter MultiCenter, Dose, Dose-Ascension Study of the p38 MAPK inhibitor Ascension Study of the p38 MAPK inhibitor Scio-469 in Patients with Myelodysplastic Syndromes (MDS) 469 in Patients with Myelodysplastic Syndromes (MDS). Am Soc Hematol, 108, p. 2657.
62. Raza, A., Candoni, A., Khan, U., Lisak, L., Tahir, S. Silvestri, F. et al. (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma, 45, pp. 2099-2104.